GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

MH Noyan-Ashraf, MA Momen, K Ban, AM Sadi… - Diabetes, 2009 - Am Diabetes Assoc
OBJECTIVE Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2
diabetes, and transient GLP-1 administration improved cardiac function in humans after …
被引用次数：691 相关文章

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

MH Noyan-Ashraf, MA Momen, K Ban, AM Sadi… - …, 2009 - pubmed.ncbi.nlm.nih.gov
Objective Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2
diabetes, and transient GLP-1 administration improved cardiac function in humans after …
[PDF] psu.edu

[PDF][PDF] GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

DJ Drucker - DIABETES, 2009 - Citeseer
OBJECTIVE—Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2
diabetes, and transient GLP-1 administration improved cardiac function in humans after …

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

MH Noyan-Ashraf, MA Momen, K Ban, AM Sadi… - Diabetes, 2009 - europepmc.org
Objective Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2
diabetes, and transient GLP-1 administration improved cardiac function in humans after …
[PDF] researchgate.net

[PDF][PDF] GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

DJ Drucker - DIABETES, 2009 - researchgate.net
OBJECTIVE—Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2
diabetes, and transient GLP-1 administration improved cardiac function in humans after …
[PDF] glucagon.com

[PDF][PDF] GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

DJ Drucker - DIABETES, 2009 - glucagon.com
OBJECTIVE—Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2
diabetes, and transient GLP-1 administration improved cardiac function in humans after …

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

MH Noyan-Ashraf, MA Momen, K Ban, AM Sadi… - Diabetes, 2009 - scholars.cityu.edu.hk
OBJECTIVE-Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2
diabetes, and transient GLP-1 administration improved cardiac function in humans after …
[PDF] utoronto.ca

[PDF][PDF] GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

DJ Drucker - DIABETES, 2009 - hsrlce.utoronto.ca
OBJECTIVE—Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2
diabetes, and transient GLP-1 administration improved cardiac function in humans after …
[PDF] glucagon.com

[PDF][PDF] GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

DJ Drucker - DIABETES, 2009 - glucagon.com
OBJECTIVE—Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2
diabetes, and transient GLP-1 administration improved cardiac function in humans after …

[引用][C] GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

MH NOYAN-ASHRAF… - … (New York, NY), 2009 - pascal-francis.inist.fr
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes
After Experimental Myocardial Infarction in Mice CNRS Inist Pascal-Francis CNRS Pascal …